WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

David T. Rubin  1     Irene Modesto  2     Severine Vermeire  3     Silvio Danese  4     Siew C. Ng  5     Nana Koram  6     Kenneth Kwok  6     Thomas V Jones  7    
1 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States
2 Pfizer Inc, New Yor, United States
3 University Hospitals Leuven, Leuven, Belgium
4 Humanitas University, Milan, Italy
5 LKS Institute of Health Science, Chinese University of Hong Kong, Institute of Digestive Disease, Hong Kong, Hong Kong
6 Pfizer Inc, New York, United States
7 Pfizer Inc, Collegeville, United States

Topic
IBD

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing